Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging

Adrian Chrastina, Jan E SchnitzerProteogenomics Research Institute for Systems Medicine, San Diego, CA, USAAbstract: Silver nanoparticles are increasingly finding applications in medicine; however, little is known about their in vivo tissue distribution. Here, we have developed a rapid method for ra...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Adrian Chrastina, Jan E Schnitzer
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ace6f29459804d86ae31044e1d1c8443
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ace6f29459804d86ae31044e1d1c8443
record_format	dspace
spelling	oai:doaj.org-article:ace6f29459804d86ae31044e1d1c84432021-12-02T05:02:08ZIodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging1176-91141178-2013https://doaj.org/article/ace6f29459804d86ae31044e1d1c84432010-09-01T00:00:00Zhttp://www.dovepress.com/iodine-125-radiolabeling-of-silver-nanoparticles-for-in-vivo-spect-ima-a5174https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Adrian Chrastina, Jan E SchnitzerProteogenomics Research Institute for Systems Medicine, San Diego, CA, USAAbstract: Silver nanoparticles are increasingly finding applications in medicine; however, little is known about their in vivo tissue distribution. Here, we have developed a rapid method for radiolabeling of silver nanoparticles with iodine-125 in order to track in vivo tissue uptake of silver nanoparticles after systemic administration by biodistribution analysis and single-photon emission computerized tomography (SPECT) imaging. Poly(N-vinyl-2-pyrrolidone)-capped silver nanoparticles with an average size of 12 nm were labeled by chemisorption of iodine-125 with a &gt;80% yield of radiolabeling efficiency. Radiolabeled silver nanoparticles were intravenously injected in Balb/c mice, and the in vivo distribution pattern of these nanoparticles was evaluated by noninvasive whole-body SPECT imaging, which revealed uptake of the nanoparticles in the liver and spleen. Biodistribution analysis confirmed predominant accumulation of the silver nanoparticles in the spleen (41.5%ID/g) and liver (24.5%ID/g) at 24 h. Extensive uptake in the tissues of the reticuloendothelial system suggests that further investigation of silver nanoparticle interaction with hepatic and splenic tissues at the cellular level is critical for evaluation of the in vivo effects and potential toxicity of silver nanoparticles. This method enables rapid iodine-125 radiolabeling of silver nanoparticles with a specific activity sufficient for in vivo imaging and biodistribution analysis.Keywords: Ag nanoparticles, radiolabeling, PVP, CT-SPECT imaging Adrian ChrastinaJan E SchnitzerDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2010, Iss default, Pp 653-659 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Adrian Chrastina Jan E Schnitzer Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging
description	Adrian Chrastina, Jan E SchnitzerProteogenomics Research Institute for Systems Medicine, San Diego, CA, USAAbstract: Silver nanoparticles are increasingly finding applications in medicine; however, little is known about their in vivo tissue distribution. Here, we have developed a rapid method for radiolabeling of silver nanoparticles with iodine-125 in order to track in vivo tissue uptake of silver nanoparticles after systemic administration by biodistribution analysis and single-photon emission computerized tomography (SPECT) imaging. Poly(N-vinyl-2-pyrrolidone)-capped silver nanoparticles with an average size of 12 nm were labeled by chemisorption of iodine-125 with a &gt;80% yield of radiolabeling efficiency. Radiolabeled silver nanoparticles were intravenously injected in Balb/c mice, and the in vivo distribution pattern of these nanoparticles was evaluated by noninvasive whole-body SPECT imaging, which revealed uptake of the nanoparticles in the liver and spleen. Biodistribution analysis confirmed predominant accumulation of the silver nanoparticles in the spleen (41.5%ID/g) and liver (24.5%ID/g) at 24 h. Extensive uptake in the tissues of the reticuloendothelial system suggests that further investigation of silver nanoparticle interaction with hepatic and splenic tissues at the cellular level is critical for evaluation of the in vivo effects and potential toxicity of silver nanoparticles. This method enables rapid iodine-125 radiolabeling of silver nanoparticles with a specific activity sufficient for in vivo imaging and biodistribution analysis.Keywords: Ag nanoparticles, radiolabeling, PVP, CT-SPECT imaging
format	article
author	Adrian Chrastina Jan E Schnitzer
author_facet	Adrian Chrastina Jan E Schnitzer
author_sort	Adrian Chrastina
title	Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging
title_short	Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging
title_full	Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging
title_fullStr	Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging
title_full_unstemmed	Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging
title_sort	iodine-125 radiolabeling of silver nanoparticles for in vivo spect imaging
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/ace6f29459804d86ae31044e1d1c8443
work_keys_str_mv	AT adrianchrastina iodine125radiolabelingofsilvernanoparticlesforinvivospectimaging AT janeschnitzer iodine125radiolabelingofsilvernanoparticlesforinvivospectimaging
_version_	1718400785482514432

Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging

Ejemplares similares